Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

An FDA committee will soon make recommendations about this fall’s Covid-19 vaccines while Novavax still awaits full FDA ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Also Read: Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline The COVID-19 vaccine maker reported an earnings per share of $2.93 ...

Novavax swung to profit in the first quarter, helped by reduced costs tied to the development and sale of its COVID-19 vaccine, its only product on the market. The Maryland-based biotech has been ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended ...

Senior leaders at the FDA began pushing Moderna and Pfizer to file for full, formal approval of their COVID vaccines for ...